Corneal injuries and diseases, affecting millions worldwide, often result in slow healing, scarring, and impaired vision. Current treatments may not adequately address these issues, leaving a significant unmet need for therapies that can accelerate healing and minimize long-term damage.

Claris Biotherapeutics is developing a topical formulation of recombinant human deleted hepatocyte growth factor (dHGF) designed to enhance corneal healing and reduce scarring. This therapy aims to accelerate the natural healing process of the cornea following injuries or in response to diseases. By targeting the underlying mechanisms of corneal repair, the dHGF formulation seeks to improve visual outcomes and minimize the formation of scar tissue, which can significantly impair vision. The treatment is designed to address a range of corneal conditions, offering a potential solution for patients with sight-threatening issues.

Recombinant human deleted hepatocyte growth factor (dHGF) as the active ingredient.

Topical formulation for direct application to the cornea.

Designed to accelerate corneal healing following injury.

Aims to reduce scarring in mechanical and bacterial injury models.

Potential to reverse recent and long-term scarring induced by injury.

May improve visual outcomes in patients with corneal damage.

Epitheliotropic, anti-fibrotic, neurotrophic, and anti-inflammatory properties.

The primary target audience includes individuals affected by corneal diseases and injuries, such as corneal edema, neurotrophic keratitis, corneal ulcers, and those who have experienced chemical, thermal, or mechanical trauma to the cornea.